director Dr A Gopalakrishnan exchanges the licence agreement with Emineotech MD Evanjalist Pathrose.
Called Cadalmin LivCure extract, it is a patent-protected nutraceutical developed by the ICAR-Central Marine Fisheries Research Institute (CMFRI) from seaweeds to combat non-alcoholic fatty liver disease (NAFLD).
The CMFRI signed a memorandum of understanding (MoU) with Emineotech, a private limited company dealing with health products, for commercial production and marketing. Dr A Gopalakrishnan, Director of CMFRI signed a licence agreement with Evanjalist Pathrose, managing director of Emineotech.
A unique blend of 100 percent natural bioactive ingredients extracted from select seaweeds, the product is made of an eco-friendly green technology to improve liver health, and is the ninth nutraceutical developed by the CMFRI.
CMFRI has already commercialised nutraceuticals to combat lifestyle diseases such as type-2 diabetes, arthritis, cholesterol, hypertension, hypothyroidism and osteoporosis, besides an immunity booster.
“We have been receiving an overwhelming response from the public ever since the CMFRI developed the Cadalmin LivCure extract, which shows increasing demand for natural remedies against lifestyle diseases,” said CMFRI director, Dr A Gopalakrishnan, in a press release.
“Commercialisation of the product will be greatly beneficial to a large number of people suffering from non-alcoholic fatty liver disease as it helps improve liver health, reduce disposition of fatty substance and maintain other liver/lipid parameters within the clinically acceptable limits,” he added. The nutraceutical does not have any side-effects as established by detailed pre-clinical trials.
“Realising the high pharmaceutical and medicinal potential of seaweeds, CMFRI launched efforts to the large-scale farming of the seaweeds across the coastal states of the country,” he continued.
Dr Kajal Chakraborty, principal scientist at the marine biotechnology, fish nutrition and health division of the CMFRI led the research to develop the product.
The product will hit the market within four months and will be made available on Amazon, Flipkart and other leading e-commerce platforms for online sale, apart from physical market networks across the country, said Pathrose.
He added that the company would also introduce initiatives for creating community awareness of the potential risk of non-symptomatic fatty liver disease and the benefits of natural cures, including lifestyle changes.
